Currently, the MDM2 inhibitor milademetan is being combined with fulvestrant to treat ER+/HER2-advanced breast cancer patients with GTAG3 mutations in tumors and/or ctDNA (Figure 12B). Here, ESR1 is linked to breast cancer.